Saxagliptin Hydrochloride
Saxagliptin hydrochloride is the hydrochloride salt of saxagliptin, a selective DPP-4 inhibitor that prolongs the activity of incretin hormones GLP-1 and GIP to stimulate glucose-dependent insulin secretion and suppress glucagon in type 2 diabetes. By inhibiting DPP-4, it prevents rapid degradation of endogenous incretins, enhancing postprandial glucose control with a low risk of hypoglycemia. It is used as monotherapy or in combination with other antidiabetic agents.
Молекулярная масса
351,9000 g/mol
TPSA
90,40 Ų
Терапевтические области
Pharmacokinetics (PK)
Pharmacodynamics (PD)
2D Структура
Cite this structure
Embed this structure
SMILES
Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2
InChI
InChI=1S/C18H25N3O2.ClH/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17;/h10-15,23H,1-7,9,20H2;1H/t10?,11?,12-,13+,14+,15-,17?,18?;/m1./s1
Molecular Formula
C18H26ClN3O2
HBD / HBA
3 / 4
Вращаемые Связи
2
Тяжёлые Атомы
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
Saxagliptin hydrochloride is the hydrochloride salt of saxagliptin, a selective DPP-4 inhibitor that prolongs the activity of incretin hormones GLP-1 and GIP to stimulate glucose-dependent insulin secretion and suppress glucagon in type 2 diabetes. By inhibiting DPP-4, it prevents rapid degradation of endogenous incretins, enhancing postprandial glucose control with a low risk of hypoglycemia. It is used as monotherapy or in combination with other antidiabetic agents.
Yes, Saxagliptin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201743. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 49800073. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="saxagliptin-hydrochloride"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/saxagliptin-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/saxagliptin-hydrochloride/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/saxagliptin-hydrochloride/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="saxagliptin-hydrochloride"></drugfyi-drug>